Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Explaining Peter Fonda’s lung cancer

Michele R. Berman, MD and Mark S. Boguski, MD, PhD
Conditions
September 3, 2019
1K Shares
Share
Tweet
Share

Actor Peter Fonda, son of Henry Fonda and younger brother of Jane Fonda, passed away August 16 at his Los Angeles home. Fonda, who was 79, is probably best known for his role as Wyatt in Easy Rider, a movie he co-wrote, produced, and starred in. Fonda was nominated for the Academy Award for Best Original Screenplay for that film as well as the Academy Award for Best Actor for Ulee’s Gold. He also acted in nearly 70 other movies, with his final film, The Last Full Measure, to be released posthumously. He guest-starred in a number of TV shows, from Naked City to CSI:NY and Documentary Now!

The cause of death was respiratory failure due to lung cancer. His family wrote:

“In one of the saddest moments of our lives, we are not able to find the appropriate words to express the pain in our hearts. As we grieve, we ask that you respect our privacy. And, while we mourn the loss of this sweet and gracious man, we also wish for all to celebrate his indomitable spirit and love of life, in honor of Peter, please raise a glass to freedom.”

Sister Jane said in a statement to Page Six, “I am very sad. He was my sweet-hearted baby brother. The talker of the family. I have had beautiful alone time with him these last days. He went out laughing.”

Lung cancer statistics

The National Cancer Institute estimates that there will be almost 230,000 new cases of lung cancer in 2019, which is about 13% of all new cancer cases. They estimate that 143,000 people will die of lung cancer in 2019 (23.5% of all cancer deaths).

The earlier lung and bronchus cancer is caught, the better chance a person has of surviving five years after being diagnosed. For lung and bronchus cancer, 16.4% are diagnosed at the local stage. The 5-year survival for localized lung and bronchus cancer is 57.4%. This drops to 30.8% for regional cancer and 5.2% for distant (metastatic) cancer.

Early diagnosis of lung cancer

Because the outcome for lung cancer patients is so dependent on the stage at which cancer is detected, researchers have been looking at ways to make the diagnosis earlier. Several methods are currently being studied to see if they decrease the risk of dying from lung cancer.

CT scan

The NCI-sponsored National Lung Screening Trial (NLST) compared two ways of detecting lung cancer: low-dose helical computed tomography (CT) — often referred to as spiral CT — and standard chest X-ray. Helical CT uses a faster machine that spins continuously around the body to obtain a multiple-image scan of the entire chest. It can also detect small nodules (early-stage lung disease) that cannot be clearly seen on chest X-rays.

The NLST enrolled 53,454 current or former heavy smokers ages 55 to 74. Participants were required to have a smoking history of at least 30 pack-years and were either current or former smokers without signs, symptoms, or history of lung cancer.

The study findings reveal that participants who received low-dose helical CT scans had a 15% to 20% lower risk of dying from lung cancer than participants who received standard chest X-rays. This is equivalent to approximately three fewer deaths per 1,000 people screened in the CT group compared to the chest X-ray group over a period of about seven years of observation (17.6 per 1,000 vs. 20.7 per 1,000, respectively).

On average, over the three rounds of screening exams, 24.2% of the low-dose helical CT screens were positive, and 6.9% of the chest X-rays were positive. In both arms of the trial, most positive screens led to additional tests.

Adenocarcinomas and squamous cell carcinomas were detected more frequently at the earliest stage by low-dose helical CT compared to chest X-ray. Small-cell lung cancers, which are very aggressive, were infrequently detected at early stages by low-dose helical CT or chest X-ray.

Biomarkers in blood

Lung cancer includes two main types: non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC is the more common type, comprising more than 80% of all lung cancer cases.

Deeper investigation of molecular abnormalities in lung cancer has identified several specific driver mutations and biomarkers that play critical roles in the development of lung cancer, particularly NSCLC. These biomarkers have been found to have predictive and prognostic significance and have a major impact on the selection of treatment. Until recently, tissue biopsy has been the gold standard for molecular analysis. However, analysis of blood samples, referred to as “liquid biopsies,” have been introduced and may hold the promise of enabling, in a less invasive way, early detection, optimizing treatment, as well as monitoring treatment response.

Biomarkers from cancer cells can be found in the blood in small amounts. They include tumor-associated antigens (TAAs), tumor-associated autoantibodies (TAAbs), circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNA (miRNA), and exosomes. ctDNA and CTCs are the most widely investigated markers in liquid biopsies of patients with NSCLC.

ctDNA consists of cell-free (cf) fragments of DNA shed into the bloodstream by tumor cells undergoing necrosis or apoptosis. It is tumor-specific and occurs in greater quantities in patients with tumors than in healthy populations. The quantity of cfDNA correlates with the level of disease burden and tumor stage, giving it a potential role in diagnosis and prognosis. One study in 2003 showed “that higher levels of free circulating DNA can be detected in patients with lung cancer compared with disease-free heavy smokers by a PCR assay, and suggests a new, noninvasive approach for early detection of lung cancer. Levels of plasma DNA could also identify higher-risk individuals for lung cancer screening and chemoprevention trials.”

A multicenter study, led by researchers at Johns Hopkins University, assessed the sensitivity and specificity of a liquid biopsy called CancerSEEK to detect the early stages of 8 common cancer types (ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast). CancerSEEK measures eight circulating proteins and 16 mutations in ctDNA. They applied the test to 1,005 patients with nonmetastatic, clinically detected cancers (of the types above). CancerSEEK was positive in about 70% of the eight cancer types, with a specificity greater than 99% (only 7 out of 812 healthy controls scored positive).

Stanford researchers, using the Cancer Personalized Profiling method by deep Sequencing (CAPP-Seq), detected cfDNA in 100% of NSCLC patients with stages II-IV and in 50% of patients with stage I disease. In addition, “levels of ctDNA significantly correlated with tumor volume, distinguished between residual disease and treatment-related imaging changes, and provided earlier response assessment than radiographic approaches,” the investigators wrote.

There is currently only one FDA-approved liquid biopsy test available for the early detection of cancer. Cobas EGFR Mutation Test v2 is a blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in NSCLC patients. It is used as a companion diagnostic for the cancer drug erlotinib (Tarceva) in NSCLC.

Several other companies are currently seeking FDA approval for liquid biopsy tests. The FDA granted “breakthrough device” designation to Guardant Health for the Guardant360 assay in February 2018, and in April 2018 to a Foundation Medicine assay.

In summary, analysis of ctDNA is a very promising new approach for cancer diagnosis and management, including monitoring the response to therapy and detecting disease recurrence. In terms of a population screening tool, akin to PSA for prostate cancer, much more research is needed on the sensitivity, specificity, and cost-effectiveness of ctDNA analysis. For more information, see “The Promise of Liquid Biopsies in the Management of Lung Cancer” at the Cancer Network website.

Michele R. Berman and Mark S. Boguski are founders, Celebrity Diagnosis. This article originally appeared in MedPage Today.

Image credit: Shutterstock.com

Prev

How this resident physician managed to stay happy and resilient in medicine

September 3, 2019 Kevin 0
…
Next

A primary care physician's decisions are questioned and second-guessed daily

September 3, 2019 Kevin 7
…

Tagged as: Oncology/Hematology, Pulmonology

Post navigation

< Previous Post
How this resident physician managed to stay happy and resilient in medicine
Next Post >
A primary care physician's decisions are questioned and second-guessed daily

More by Michele R. Berman, MD and Mark S. Boguski, MD, PhD

  • Physicians explain Sia’s chronic pain

    Michele R. Berman, MD and Mark S. Boguski, MD, PhD
  • The mystery illness of Kim Kardashian West

    Michele R. Berman, MD and Mark S. Boguski, MD, PhD
  • Elon Musk’s girlfriend had eye surgery for depression. Is there science behind that?

    Michele R. Berman, MD and Mark S. Boguski, MD, PhD

Related Posts

  • Hormone replacement therapy is still linked to cancer

    Martha Rosenberg
  • When breast cancer screening guidelines conflict: Some patients face real consequences

    Leda Dederich
  • Cancer care costs everyone too much. What can we do about it?

    Andrew Hertler, MD
  • COVID is not a great equalizer

    Ritodhi Chatterjee
  • Fight gun violence with science

    Jamie Coleman, MD
  • 6 unconscious biases against vitamins and supplements

    Melinda Ring, MD

More in Conditions

  • Overcoming the lies of depression: Senator John Fetterman’s struggle with mental health

    Harvey Max Chochinov, MD, PhD
  • Proposed USPSTF guideline update: Advocating for earlier breast cancer screening at age 40

    Hoag Memorial Hospital Presbyterian
  • The rising threat of lung cancer in Asian American female nonsmokers

    Alice S. Y. Lee, MD
  • Urgent innovation needed to address growing mental health crisis among children and families

    Monika Roots, MD
  • The importance of listening in health care: a mother’s journey advocating for children with chronic Lyme disease

    Cheryl Lazarus
  • The unjust reality of racial disparities in pediatric kidney transplants

    Lien Morcate
  • Most Popular

  • Past Week

    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • Unlocking resilience: a powerful journey from trauma to transformation [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • An inspiring tribute to an exceptional radiologist who made a lasting impact

      Kim Downey, PT | Conditions
  • Recent Posts

    • Unlocking resilience: a powerful journey from trauma to transformation [PODCAST]

      The Podcast by KevinMD | Podcast
    • Overcoming the lies of depression: Senator John Fetterman’s struggle with mental health

      Harvey Max Chochinov, MD, PhD | Conditions
    • Master the ABIM Certification exam with effective strategies: insider tips for success

      Farzana Hoque, MD | Education
    • A mentor’s legacy in medicine, leadership, and embracing evidence-based care

      Arthur Lazarus, MD, MBA | Physician
    • Breaking free from restrictive covenants to combat burnout

      Raya E. Kheirbek, MD | Physician
    • Fixing the system and prioritizing patient care [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • New Data in NSCLC Bolster Support for Perioperative Immunotherapy
  • Breathing Support Type Matters for Preventing Extubation Failure in the PICU
  • Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma
  • New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials
  • Kratom Linked to Outsized Proarrhythmic Risks

Meeting Coverage

  • New Data in NSCLC Bolster Support for Perioperative Immunotherapy
  • Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma
  • New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials
  • CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma
  • T-DXd Proves Mettle in Multiple Solid Tumors
  • Most Popular

  • Past Week

    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • Unlocking resilience: a powerful journey from trauma to transformation [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • An inspiring tribute to an exceptional radiologist who made a lasting impact

      Kim Downey, PT | Conditions
  • Recent Posts

    • Unlocking resilience: a powerful journey from trauma to transformation [PODCAST]

      The Podcast by KevinMD | Podcast
    • Overcoming the lies of depression: Senator John Fetterman’s struggle with mental health

      Harvey Max Chochinov, MD, PhD | Conditions
    • Master the ABIM Certification exam with effective strategies: insider tips for success

      Farzana Hoque, MD | Education
    • A mentor’s legacy in medicine, leadership, and embracing evidence-based care

      Arthur Lazarus, MD, MBA | Physician
    • Breaking free from restrictive covenants to combat burnout

      Raya E. Kheirbek, MD | Physician
    • Fixing the system and prioritizing patient care [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...